(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 7.59% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 10.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.63%.
Johnson & Johnson's revenue in 2025 is $79,833,000,000.On average, 1 Wall Street analysts forecast JNJ's revenue for 2025 to be $215,886,206,976,242, with the lowest JNJ revenue forecast at $215,886,206,976,242, and the highest JNJ revenue forecast at $215,886,206,976,242. On average, 6 Wall Street analysts forecast JNJ's revenue for 2026 to be $227,469,283,502,157, with the lowest JNJ revenue forecast at $221,804,625,766,013, and the highest JNJ revenue forecast at $232,090,039,254,856.
In 2027, JNJ is forecast to generate $239,400,786,409,334 in revenue, with the lowest revenue forecast at $232,624,531,554,640 and the highest revenue forecast at $246,177,041,264,028.